Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its ...
Fourth Quarter and Full Year 2023 Financial Results Net loss for the quarter and full year ended December 31, 2023 was $19.3 million and $60.4 million, respectively. This compares to a net loss of ...
A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, "ABT199/venetoclax synergism with ...
Actress Olivia Munn recently shared on social media that she had undergone a double mastectomy after being diagnosed with ...
A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine ...
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology ...